arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

C4 Therapeutics, Inc.

CCCC Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$3.76
Today
as of Sep 4, 16:47 ET
Last 30 days +4.74% Jul 27 → Sep 04
$3.42 $3.64 $3.87 $4.10 $4.33 Jul 27 Aug 04 Aug 12 Aug 19 Aug 27 Sep 04
Open
$3.72
High
$3.84
Low
$3.66
Volume
$2M
Avg Vol
$2M
Mkt Cap
$502M
P/E (TTM)
—
Beta
—
52w High
$5.17
52w Low
$1.69
Div Yield
—
Shares Out
$123M

Recent Press Releases & News last 60 days · 2 items

Aug 21 · 16:00 Zacks
Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice
Aug 11 · 12:15 Zacks
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates

Overview

52-week range
$1.69
$5.17
59% of range
Avg surprise (last 3)
+10.1%
Avg reaction (last 2)
+3.2%
50% positive
Latest IV / EM
119%
EM ±18.6% · $4 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.73$-0.59$-0.45$-0.32$-0.18 Actual $-0.71Actual $-0.73Actual $-0.55Actual $-0.41Actual $-0.26Actual $-0.35Actual $-0.37Est $-0.48Actual $-0.37Est $-0.38Actual $-0.44Actual $-0.20Est $-0.21Actual $-0.18 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-32M$-20M$-8M$4M$16M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.18 — — — — financials
Tue May 12, 2026Mar/2026 $-0.20 $-0.21 +4.8% +46.0% 0.0% earnings
Tue Sep 30, 2025Sep 2025 $-0.44 — — — — financials
Thu Aug 7, 2025Jun/2025 $-0.37 $-0.38 +2.6% — — earnings
Wed May 7, 2025Mar/2025 $-0.37 $-0.48 +22.9% — +6.4% earnings
Mon Sep 30, 2024Sep 2024 $-0.35 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.26 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.41 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.55 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.73 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.71 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$7M$6M—$11M$6M$7M—$15M
Cost of revenue————————
Gross profit————————
Operating income$-26M$-28M—$-34M$-29M$-29M—$-28M
Net income$-24M$-25M—$-32M$-26M$-26M—$-25M
EPS (diluted)$-0.18$-0.20—$-0.44$-0.37$-0.37—$-0.35

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$79M$61M$75M$59M$78M$51M$55M$60M
Inventory————————
Total current assets$263M$245M$258M$207M$225M$233M$258M$273M
Total assets$359M$329M$359M$265M$297M$320M$350M$376M
Long-term debt————————
Total liabilities$112M$95M$102M$111M$122M$124M$134M$133M
Total equity$247M$234M$257M$154M$174M$195M$216M$243M

Implied volatility — last 90 days

49%170%290%410%530% Jun 07 — IV 188% · EM ±26.0%Jun 08 — IV 169% · EM ±22.3%Jun 09 — IV 173% · EM ±21.6%Jun 10 — IV 135% · EM ±15.9%Jun 11 — IV 170% · EM ±18.7%Jun 12 — IV 150% · EM ±15.4%Jun 15 — IV 109% · EM ±7.9%Jun 19 — IV 117% · EM ±25.9%Jun 22 — IV 78% · EM ±16.4%Jun 23 — IV 116% · EM ±23.7%Jun 24 — IV 147% · EM ±29.4%Jun 25 — IV 110% · EM ±21.5%Jun 26 — IV 104% · EM ±20.0%Jun 29 — IV 162% · EM ±28.7%Jun 30 — IV 154% · EM ±26.6%Jul 01 — IV 179% · EM ±30.0%Jul 02 — IV 122% · EM ±19.8%Jul 03 — IV 126% · EM ±19.8%Jul 06 — IV 139% · EM ±19.2%Jul 07 — IV 139% · EM ±18.4%Jul 08 — IV 162% · EM ±20.3%Jul 09 — IV 148% · EM ±17.5%Jul 13 — IV 153% · EM ±12.8%Jul 14 — IV 218% · EM ±15.7%Jul 15 — IV 67% · EM ±3.9%Jul 16 — IV 531% · EM ±22.2%Jul 20 — IV 157% · EM ±37.2%Jul 21 — IV 112% · EM ±26.1%Jul 22 — IV 88% · EM ±20.1%Jul 23 — IV 134% · EM ±30.1%Jul 24 — IV 100% · EM ±22.1%Jul 27 — IV 117% · EM ±24.4%Jul 28 — IV 169% · EM ±34.5%Jul 29 — IV 149% · EM ±29.8%Jul 30 — IV 143% · EM ±28.0%Jul 31 — IV 120% · EM ±23.0%Aug 03 — IV 194% · EM ±34.3%Aug 04 — IV 113% · EM ±19.4%Aug 05 — IV 141% · EM ±23.5%Aug 06 — IV 136% · EM ±22.0%Aug 07 — IV 142% · EM ±22.1%Aug 10 — IV 145% · EM ±20.0%Aug 11 — IV 157% · EM ±20.7%Aug 12 — IV 102% · EM ±12.8%Aug 13 — IV 166% · EM ±19.6%Aug 14 — IV 160% · EM ±17.7%Aug 17 — IV 182% · EM ±15.2%Aug 18 — IV 232% · EM ±16.7%Aug 19 — IV 241% · EM ±14.3%Aug 24 — IV 85% · EM ±17.7%Aug 25 — IV 76% · EM ±15.5%Aug 26 — IV 86% · EM ±17.3%Aug 27 — IV 50% · EM ±9.8%Aug 28 — IV 98% · EM ±18.8%Aug 31 — IV 145% · EM ±25.6%Sep 01 — IV 104% · EM ±17.9%Sep 02 — IV 95% · EM ±15.8%Sep 03 — IV 107% · EM ±17.4%Sep 04 — IV 119% · EM ±18.6%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in